256 related articles for article (PubMed ID: 34269950)
21. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
[TBL] [Abstract][Full Text] [Related]
22. Recent advancements in the molecular biology of pituitary adenomas.
Zheng AC; Wang EJ; Aghi MK
Expert Rev Endocrinol Metab; 2022 Jul; 17(4):293-304. PubMed ID: 35702013
[TBL] [Abstract][Full Text] [Related]
23. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
24. Newer Concepts in the Classification of Pituitary Adenomas.
Sathyakumar R; Chacko G
Neurol India; 2020; 68(Supplement):S7-S12. PubMed ID: 32611886
[TBL] [Abstract][Full Text] [Related]
25. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
26. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
27. Expression of leukemia inhibitory factor in human pituitary adenomas: a morphologic and immunocytochemical study.
Kontogeorgos G; Patralexis H; Tran A; Kovacs K; Melmed S
Pituitary; 2000 May; 2(4):245-51. PubMed ID: 11081145
[TBL] [Abstract][Full Text] [Related]
28. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
Nf L; Ai M
Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
[TBL] [Abstract][Full Text] [Related]
29. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Raverot G; Roncaroli F; Villa C
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098443
[TBL] [Abstract][Full Text] [Related]
30. Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.
Saeger W; Koch A
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):146-156. PubMed ID: 33690870
[TBL] [Abstract][Full Text] [Related]
31. Clinical Impact of the Current WHO Classification of Pituitary Adenomas.
Saeger W; Honegger J; Theodoropoulou M; Knappe UJ; Schöfl C; Petersenn S; Buslei R
Endocr Pathol; 2016 Jun; 27(2):104-14. PubMed ID: 26860936
[TBL] [Abstract][Full Text] [Related]
32. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
[TBL] [Abstract][Full Text] [Related]
33. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
34. Expression and mutation analysis of Tpit in the canine pituitary gland and corticotroph adenomas.
Hanson JM; Mol JA; Leegwater PA; Bilodeau S; Drouin J; Meij BP
Domest Anim Endocrinol; 2008 Apr; 34(3):217-22. PubMed ID: 17544240
[TBL] [Abstract][Full Text] [Related]
35. Current pathological classification of pituitary adenomas.
Saeger W
Acta Neurochir Suppl; 1996; 65():1-3. PubMed ID: 8738481
[TBL] [Abstract][Full Text] [Related]
36. Silent familial isolated pituitary adenomas: histopathological and clinical case report.
Villa C; Magri F; Morbini P; Falchetti A; Scagnelli P; Lovati E; Locatelli D; Canevari FR; Necchi V; Gabellieri E; Guabello G; Chiovato L; Solcia E
Endocr Pathol; 2008; 19(1):40-6. PubMed ID: 18317953
[TBL] [Abstract][Full Text] [Related]
37. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
[TBL] [Abstract][Full Text] [Related]
38. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
39. Advances and controversies in the classification and grading of pituitary tumors.
Laws ER; Penn DL; Repetti CS
J Endocrinol Invest; 2019 Feb; 42(2):129-135. PubMed ID: 29858984
[TBL] [Abstract][Full Text] [Related]
40. Novel Genetic Causes of Pituitary Adenomas.
Caimari F; Korbonits M
Clin Cancer Res; 2016 Oct; 22(20):5030-5042. PubMed ID: 27742789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
